Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Nagawa-machi, Chisagata-gun, Japan Clinical Trials

A listing of Nagawa-machi, Chisagata-gun, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

Non-interventional Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

This local, prospective, non-interventional, company sponsored, multi-center, single-cohort study includes patients treated with Ventavis for PAH. A total of 270 patients (valid for safety analysis) is planned to be enrolled in 5 years. Target population is patients with PAH diagnosis. This study is performed as an all-patient investigation, therefore all ...

Phase N/A

4.51 miles

Learn More »

Drug Use Investigation of Kovaltry in Hemophilia A Patients

This company-sponsored study is a single-arm, prospective, observational study in hemophilia A patients administered Kovaltry. 200 cases will be planned to be registered as safety analysis set in three-year period. Within 200 cases, 50 cases less than 12 years old will be planned to be registered. Target population are all ...

Phase N/A

4.51 miles

Learn More »

All-Case Surveillance of Prizbind

To evaluate safety and effectiveness of Prizbind for Intravenous Solution 2.5 g under Japanese clinical condition

Phase N/A

4.51 miles

Learn More »

Prospective Non-interventional Multi-center Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

This local, prospective, non-interventional, multi-center study includes patients treated with Riociguat for PAH. A total of 600 patients (valid for safety analysis) is planned to be included in 4 years. This study is performed as an "all-case investigation" therefore; all patients who receive Riociguat treatment for PAH need to be ...

Phase N/A

4.51 miles

Learn More »

Regorafenib Post-marketing Surveillance in Japan

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy. A total of 135 patients are to be enrolled and assessed in 6 months standard observational period. At ...

Phase N/A

4.51 miles

Learn More »

Prospective Non-interventional Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )

This local, prospective, non-interventional, multi-center study includes patients treated with Riociguat for inoperable CTEPH(Chronic thromboembolic pulmonary hypertension)/ persistent or recurrent CTEPH after surgical treatment. It is planned to include a total of 400 patients (valid for safety analysis). This study is performed as an all-case investigation. The treatment of Riociguat ...

Phase N/A

4.51 miles

Learn More »

Prospective Non-interventional Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within a certain period. The investigator should have made the choice of treatment (NEXAVAR) according with the Japanese Package Insert prior to enrolling the patient in ...

Phase N/A

4.51 miles

Learn More »

Zevalin Post-marketing Surveillance in Japan

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma. The objective of this study is to assess safety and efficacy ...

Phase N/A

4.51 miles

Learn More »

Brilinta Clinical Experience Investigation

To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase. Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on ...

Phase N/A

4.51 miles

Learn More »

Study on the Safety of the Approved Product Empedic L Cream During Its Routine Use (Active Ingredient is Clotrimazole 1%)

Researchers already did trials that showed Empecid L Cream worked for patients with Vaginal yeast infection who were in those trials. In this trial, they want to learn if consumers that use the cream under the guidance of a pharmacist have any medical problems during the trial.

Phase N/A

4.51 miles

Learn More »